Caution in Using the Activated Partial Thromboplastin Time to Monitor Argatroban in COVID-19 and Vaccine-Induced Immune Thrombocytopenia and Thrombosis (VITT)

INTRODUCTION: Argatroban is licensed for patients with heparin-induced thrombocytopenia and is conventionally monitored by activated partial thromboplastin time (APTT) ratio. The target range is 1.5 to 3.0 times the patients’ baseline APTT and not exceeding 100 s, however this baseline is not always...

Descripción completa

Detalles Bibliográficos
Autores principales: Guy, Susan, Kitchen, Steve, Makris, Michael, M. Maclean, Rhona, Saccullo, Giorgia, Vanveen, Joost J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2021
Materias:
Original Manuscript
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8689594/
https://www.ncbi.nlm.nih.gov/pubmed/34905962
http://dx.doi.org/10.1177/10760296211066945

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8689594/
https://www.ncbi.nlm.nih.gov/pubmed/34905962
http://dx.doi.org/10.1177/10760296211066945

Ejemplares similares